Thyrocare Technologies Ltd
Please find attached the Press Release on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 23 Jul 2026, 04:01 PM IST · BSE ID: 182da29f-d93a-461d-abf4-6087cb0beb6f
View Original BSE Filing (PDF)
💡
In Simple Terms
Thyrocare Technologies' latest financial results show significant growth in sales and profits for the recent quarter.
🤖 AI Summary
- Consolidated revenue for Q1FY27 reached INR 240.02 Cr, a 24% year-on-year growth.
- Consolidated EBITDA grew 34% year-on-year to INR 77.27 Cr in Q1FY27.
- Profit After Tax (PAT) increased 34% year-on-year to INR 51.33 Cr.
- Thyrocare processed 55.2 million tests in Q1FY27, marking a 28% year-on-year growth.
- The company expanded its operations into Specialty Diagnostics, starting with Allergy and Genomics.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue Q1FY27
INR 240.02 Cr
24%
Consolidated EBITDA Q1FY27
INR 77.27 Cr
34%
Profit After Tax (PAT) Q1FY27
INR 51.33 Cr
34%
Tests Processed Q1FY27
55.2 million tests
28%
Pathology Segment Growth Q1FY27
26%
🏢 How This Affects the Company
The company's revenue growth of 24% YoY, driven by a 26% increase in the Pathology segment, reinforces its market position. Expansion into Specialty Diagnostics, including Allergy and Genomics, diversifies its service portfolio and growth avenues.
Consolidated EBITDA grew by 34% YoY to INR 77.27 Cr and Profit After Tax (PAT) increased by 34% YoY to INR 51.33 Cr, indicating improved profitability. Increased test volumes of 55.2 million also suggest sustained operational scale.
Processing 55.2 million tests with a 28% YoY growth demonstrates enhanced operational capacity and efficiency. Reduction in complaints per million tests to 3.1 and ATAT at 3.37 hours indicate operational quality improvements.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results disclosure.
👤
Who Is Affected
All shareholders are affected as the company's financial performance influences its underlying value. Strong growth in revenue and profits could strengthen the company's financial position.
🔍
Management Signal
Management is focused on driving profitable growth through operational efficiency, network expansion, and diversifying into specialty diagnostics, as indicated by the launch of Allergy and Genomics testing.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — monitor sustained revenue and profit growth.
Updates on Specialty Diagnostics expansion — track new test portfolio additions.
Changes in franchise and partnership revenue growth rates in future quarters.
LOW RISK
The filing reports strong financial performance with no immediate risks identified.
💡 Investor Takeaway
Thyrocare Technologies reported consolidated revenue of INR 240.02 Cr in Q1FY27, a 24% YoY increase. Profit After Tax grew 34% YoY to INR 51.33 Cr, driven by a 26% growth in the Pathology segment. Test volumes rose 28% YoY to 55.2 million.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated revenue registered a 24% year-on-year growth to INR 240.02 Cr, primarily driven by a 26% increase in the Pathology segment.
- Consolidated EBITDA grew by 34% year-on-year to INR 77.27 Cr, and Profit After Tax (PAT) grew by 34% year-on-year to INR 51.33 Cr.
📅 Company Track Record
Thyrocare Technologies' board approved Q1 FY27 results on July 23, 2026, and re-appointed an internal auditor for FY26-27. The company also announced an earnings call for Q1 FY27 on July 23, 2026, following the release of these results.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Thyrocare Technologies' consolidated revenue for Q1FY27?
Thyrocare Technologies reported consolidated revenue of INR 240.02 Cr for the quarter ended June 30, 2026, representing a 24% year-on-year growth.
What was the Profit After Tax (PAT) for Thyrocare Technologies in Q1FY27?
The Profit After Tax (PAT) for Thyrocare Technologies in Q1FY27 was INR 51.33 Cr, showing a 34% year-on-year growth.
How many tests did Thyrocare Technologies process in Q1FY27?
Thyrocare Technologies processed 55.2 million tests in Q1FY27, which is a 28% year-on-year growth.
What was the growth in the Pathology segment for Thyrocare Technologies in Q1FY27?
The Pathology segment for Thyrocare Technologies registered a 26% year-on-year growth in Q1FY27, driving overall revenue.
Questions based on this BSE filing only. For information purposes.